Key result
Dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients with arterial vascular disease, but not in asymptomatic patients.
Why the study?
Does dual antiplatelet therapy with aspirin and clopidogrel improve outcomes compared to aspirin monotherapy in patients with arterial vascular disease?
Does dual antiplatelet therapy with aspirin and clopidogrel improve outcomes compared to aspirin monotherapy in patients with arterial vascular disease?
Dual antiplatelet therapy with aspirin and clopidogrel provides clinical benefit in acute, high-risk symptomatic vascular settings but is not justified for stable or asymptomatic patients due to hemorrhagic risk.
Supports targeted DAPT in high-risk symptomatic arterial disease; leaves open net benefit in asymptomatic patients.
The focus of this review is to discuss the hypothesis that justifies the use of dual antiplatelet therapy of aspirin and clopidogrel versus monotherapy with aspirin in arterial vascular disease. By analyzing the CLARITY-TIMI and COMMIT trials, the authors discuss the appropriate use of aspirin plus clopidogrel for patients suffering acute myocardial infarction. In contrast, in the CHARISMA trial, the combination was not justified in stable high-risk patients with documented coronary disease, cerebrovascular disease or symptomatic peripheral artery disease. In two additional cardiovascular studies, the CURE and the PCI-CURE trials, the benefit of the drug combination was evident in those patients who underwent percutaneous coronary intervention and coronary artery bypass grafting. Finally, two focused cerebrovascular studies, the CARESS and the MATCH trials, were analyzed. The CARESS trial demonstrated the clinical benefit of this combination in an acute clinical setting. However, the combination proved to be ineffective in the longer-term MATCH trial. It appears from these large clinical trials that the risk-benefit of dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients but not in asymptomatic patients. The exact dose regimen and duration of combination therapy await definition and require careful assessment to optimize the anticoagulant benefit, while minimizing the hemorrhagic risk.
No takes yet. Share an insight, caveat, or question.
Fares et al. (2008) conducted a review in Arterial vascular disease. Dual antiplatelet therapy (aspirin and clopidogrel) vs. Aspirin monotherapy was evaluated. Dual antiplatelet therapy with aspirin and clopidogrel is justified in high-risk symptomatic patients with arterial vascular disease, but not in asymptomatic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: